U.S.S.N. 09/981,845 FILED: October 18, 2001 **AMENDMENT**

Ip the Claims

- (currently amended) An active osteopontin peptide fragment comprising an 1. amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, wherein the peptide binds to at least one integrin receptor on a cell surface selected from the group consisting of $\alpha_{V}\beta_{3}$, $\alpha_{V}\beta_{5}$, $4\beta_{1}$, $2\beta_{1}$, VCAM, ICAM CD44, $V_{3}V_{X}$.
- (previously presented) The peptide fragment of claim 1, wherein the peptide 2. increases cell attachment to a biomaterial and increases cell spread.
- (currently amended) The peptide fragment of claim ⊋ 1, wherein the peptide 3. binds to at least one integrin receptor on a cell surface selected from the group consisting of VCAM, ICAM CD44, and V3VX.
 - (cancelled) 4.
- (currently amended) The peptide fragment of claim 3 1 wherein the integrin(s) is 5. selected from the group consisting of $\alpha_V \beta_3$, $\alpha_V \beta_5$, $4\beta_1$, and $2\beta_1$, VCAM, ICAM CD44, $V_3 V_{\chi}$.
- (currently amended) The peptide fragment of claim 3 1 wherein the cell is 6. selected from the group consisting of osteoprogenitor cells, tumor cells, macrophages, periosteal cells, endothelial cells, epithelial cells, cosinophils, stem cells, limited potential precursor cells, precursor cells, committed precursor cells, and differentiated cells.

7-18. (cancelled)